These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 34063675)

  • 1. The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.
    Agrawal S
    Biomedicines; 2021 May; 9(5):. PubMed ID: 34063675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the medicinal chemistry of antisense oligonucleotides.
    Uhlmann E
    Curr Opin Drug Discov Devel; 2000 Mar; 3(2):203-13. PubMed ID: 19649851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA Therapeutics Are Stepping Out of the Maze.
    Agrawal S
    Trends Mol Med; 2020 Dec; 26(12):1061-1064. PubMed ID: 32988738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense and/or immunostimulatory oligonucleotide therapeutics.
    Agrawal S; Kandimalla ER
    Curr Cancer Drug Targets; 2001 Nov; 1(3):197-209. PubMed ID: 12188879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in antisense oligonucleotide therapeutics.
    Crooke ST; Bennett CF
    Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Medicinal Chemistry of Therapeutic Oligonucleotides.
    Wan WB; Seth PP
    J Med Chem; 2016 Nov; 59(21):9645-9667. PubMed ID: 27434100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP
    Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of oligonucleotide-based therapeutics: challenges and opportunities.
    Hammond SM; Aartsma-Rus A; Alves S; Borgos SE; Buijsen RAM; Collin RWJ; Covello G; Denti MA; Desviat LR; Echevarría L; Foged C; Gaina G; Garanto A; Goyenvalle AT; Guzowska M; Holodnuka I; Jones DR; Krause S; Lehto T; Montolio M; Van Roon-Mom W; Arechavala-Gomeza V
    EMBO Mol Med; 2021 Apr; 13(4):e13243. PubMed ID: 33821570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicinal chemistry of antisense oligonucleotides--future opportunities.
    Cook PD
    Anticancer Drug Des; 1991 Dec; 6(6):585-607. PubMed ID: 1772571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides.
    Bege M; Borbás A
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 35893733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.
    Shen X; Corey DR
    Nucleic Acids Res; 2018 Feb; 46(4):1584-1600. PubMed ID: 29240946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicinal Chemistry of Antisense Oligonucleotides for Therapeutic Use in SARS-CoV-2: Design Strategies and Challenges for Targeted Delivery.
    Nedaeinia R; Ranjbar M; Goli M; Etebari M; Safabakhsh S; Bayram H; Ferns GA; Tehrani HM; Salehi R
    Curr Med Chem; 2024 Jun; ():. PubMed ID: 38860908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking.
    Mangla P; Vicentini Q; Biscans A
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligonucleotide therapeutics: chemistry, delivery and clinical progress.
    Sharma VK; Watts JK
    Future Med Chem; 2015; 7(16):2221-42. PubMed ID: 26510815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicinal Chemistry of Oligonucleotide Drugs - Milestones of the Past and Visions for the Future.
    Hall J; Ashkinadze A; Becker JP; Laski A; Manz EM; Moravčík Š; Sjöström S; Vincent M
    Chimia (Aarau); 2022 May; 76(5):466-473. PubMed ID: 38069719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress toward oligonucleotide therapeutics: pharmacodynamic properties.
    Crooke ST
    FASEB J; 1993 Apr; 7(6):533-9. PubMed ID: 7682523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey.
    Oberemok VV; Laikova KV; Repetskaya AI; Kenyo IM; Gorlov MV; Kasich IN; Krasnodubets AM; Gal'chinsky NV; Fomochkina II; Zaitsev AS; Bekirova VV; Seidosmanova EE; Dydik KI; Meshcheryakova AO; Nazarov SA; Smagliy NN; Chelengerova EL; Kulanova AA; Deri K; Subbotkin MV; Useinov RZ; Shumskykh MN; Kubyshkin AV
    Molecules; 2018 May; 23(6):. PubMed ID: 29844255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases.
    Ossipov DA
    Expert Opin Drug Deliv; 2019 Jun; 16(6):621-637. PubMed ID: 31072142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.